Pharmaceutical Executive December 30, 2025
Key Takeaways
- AbbVie is focusing on early-stage assets and gene therapy for retinal diseases to address unmet needs in wet AMD and DR.
- The acquisition of ImmunoGen and Cerevel Therapeutics diversifies AbbVie’s oncology and neuroscience portfolios, enhancing growth potential.
- AbbVie aims to leverage its commercial and regulatory expertise to maximize the potential of new therapies, driving long-term growth.
AbbVie has spent previous conferences detailing its work to rebuild its pipeline after losing Humira.
In 2025, AbbVie’s presentation focused on its efforts to build-up its pipeline of early-stage assets. This was part of the company’s plans to move forward from the loss of Humira, one of its key products.
2025
Around the same time as the JP Morgan conference,...
Today's Sponsors
Today's Sponsor